Acessibilidade / Reportar erro
Revista Brasileira de Hematologia e Hemoterapia, Volume: 33, Número: 3, Publicado: 2011
  • Countries emerging as major scientific powers Editorial

  • Conditioning regimen using busulfan plus melphalan in hematopoietic stem cell transplantation: can this conditioning regimen be used in autologous or allogeneic transplantation for acute leukemia? Scientific Comments

    Lemoli, Roberto M; D'Addio, Alessandra
  • Compliance and adherence of patients in the treatment of acute lymphoblastic leukemia Scientific Comments

    Barr, Ronald Duncan
  • Retention of blood donors: strategies to fulfill the requirements of blood centers Scientific Comments

    Almeida Neto, Cesar de
  • A brief explanation of the air traffic controller professional activity Scientific Comments

    Ferreira Filho, Bemildo Alvaro
  • The expression of the CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia Scientific Comments

    Rego, Eduardo Magalhães
  • Oxidative status in sickle cell anemia Scientific Comments

    Magalhães, Silvia Maria Meira
  • Busulfan and melphalan as conditioning regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia in first complete remission Original Articles

    Bueno, Nadjanara Dorna; Dulley, Frederico Luiz; Saboya, Rosaura; Amigo Filho, José Ulysses; Coracin, Fabio Luiz; Chamone, Dalton de Alencar Fischer

    Resumo em Inglês:

    BACKGROUND: Allogeneic hematopoietic stem cell transplantation with HLA-identical donors has been established for the treatment of acute myeloid leukemia patients for over 30 years with a cure rate of 50% to 60%. OBJECTIVES: To analyze the overall survival of patients and identify factors that influence the outcomes of this type of transplant in patients in 1st complete remission who received a busulfan and melphalan combination as conditioning regimen. METHODS: Twenty-five consecutive patients with acute myeloid leukemia were enrolled between 2003 and 2008. The median age was 34 years old (Range: 16 - 57 years). All patients received cyclosporine and methotrexate for prophylaxis against graft-versus-host disease. Median neutrophil engraftment time was 16 days (Range: 7 - 22 days) and 17 days (Range: 7 - 46 days) for platelets. Sinusoidal obstructive syndrome was observed in three patients, seven had grade II acute graft-versus-host disease and one extensive chronic graft-versus-host disease. RESULTS: The overall survival by the Kaplan-Meier method was 48% after 36 months with a plateau at 36 months after transplantation. Intensive consolidation with high-dose arabinoside resulted in an improved survival (p-value = 0.0001), as did grade II acute graft-versus-host disease (p-value = 0.0377) and mild chronic graft-versus-host disease (p-value < 0.0001). Thirteen patients died, five due to infection within 100 days of transplant, two due to hemorrhages, one to infection and graftversus-host disease and three relapses followed by renal failure (one) and infection (two). The cause of death could not be determined for two patients. CONCLUSION: The busulfan and melphalan conditioning regimen is as good as other conditioning regimens providing an excellent survival rate.
  • Compliance with a protocol for acute lymphoblastic leukemia in childhood Original Articles

    Oliveira, Benigna Maria de; Valadares, Maria Thereza Macedo; Silva, Marcilene Rezende; Viana, Marcos Borato

    Resumo em Inglês:

    BACKGROUND: Remission rates achieved after the initial treatment of acute lymphoblastic leukemia may be similar in both developed and developing countries, but relapse rates are much higher in the latter. Thus, other reasons are needed, in addition to biological characteristics of the leukemic cells themselves, to explain the unfavorable evolution of patients living in unfavorable socioeconomic and cultural conditions. OBJECTIVE: The aim of this study was to retrospectively evaluate compliance to an acute lymphoblastic leukemia treatment protocol. METHODS: Main abstracted data were: total duration and reasons for interruption of chemotherapy, prescribed doses of 6-mercaptopurine, and median white blood cell and neutrophil counts during the maintenance phase. Interruptions of chemotherapy were considered inappropriate if they did not follow predetermined criteria established in the protocol. RESULTS: Fourteen of 73 patients (19.2%) unduly interrupted chemotherapy by determination of their physicians. The median white blood cell count was higher when compared with the protocol recommendations; the median 6-MP dose was lower than the standard recommended dose. The estimated probability of event-free survival was higher for patients with lower median leukocyte counts and close to those predetermined by the protocol. Event-free survival was also higher for children with a higher percentage of days without chemotherapy due to bone marrow or liver toxicity excluding undue interruptions. In multivariate analysis, both factors remained statistically significant. These results suggest that the intensity of maintenance chemotherapy may not have been enough in some children, to achieve adequate myelosuppression, hence the observation of higher leukocyte counts and none or rare episodes of therapy interruption. CONCLUSIONS: Compliance to the therapeutic protocol by both doctors and patients should always be considered in the evaluation of therapeutic failure in acute lymphoblastic leukemia; strict adherence to treatment protocols contributes to better treatment results in acute lymphoblastic leukemia children.
  • Evaluation of the return rate of volunteer blood donors Original Articles

    Lourençon, Adriana de Fátima; Almeida, Rodrigo Guimarães dos Santos; Ferreira, Oranice; Martinez, Edson Zangiacomi

    Resumo em Inglês:

    BACKGROUND: To convert first-time blood donors into regular volunteer donors is a challenge to transfusion services. OBJECTIVES: This study aims to estimate the return rate of first time donors of the Ribeirão Preto Blood Center and of other blood centers in its coverage region. METHODS: The histories of 115,553 volunteer donors between 1996 and 2005 were analyzed. Statistical analysis was based on a parametric long-term survival model that allows an estimation of the proportion of donors who never return for further donations. RESULTS: Only 40% of individuals return within one year after the first donation and 53% return within two years. It is estimated that 30% never return to donate. Higher return rates were observed among Black donors. No significant difference was found in non-return rates regarding gender, blood type, Rh blood group and blood collection unit. CONCLUSIONS: The low percentage of first-time donors who return for further blood donation reinforces the need for marketing actions and strategies aimed at increasing the return rates.
  • Hematological and immunological effects of stress of air traffic controllers in northeastern Brazil Original Articles

    Ribas, Valdenilson Ribeiro; Martins, Hugo André de Lima; Viana, Marcelo Tavares; Fraga, Simone do Nascimento; Carneiro, Severino Marcos de Oliveira; Galvão, Bruno Henrique Andrade; Bezerra, Alice Andrade; Castro, Célia Maria Machado Barbosa de; Sougey, Everton Botelho; Castro, Raul Manhães de

    Resumo em Inglês:

    BACKGROUND: Several studies have shown that stress and emotional reactions can affect immune responses in animals and humans. OBJECTIVE: The aim of this study was to evaluate hematological and immunological effects of stress on air traffic controllers. METHODS: Thirty air traffic controllers and 15 aeronautical information service operators were evaluated. The groups were divided as information service operators with 10 years or more of experience (AIS>10) and with less than 10 years in the profession (AIS<10) and air traffic controllers with 10 years or more of experience (ATCo>10) and with less than 10 years in the profession (ATCo<10). Blood samples were drawn at 8:00 a.m. and 2:00 p.m. The paired t-test was used to compare monocyte and nitric oxide concentrations and ANOVA was used for the other parameters. RESULTS: The ATCo>10 group presented a significantly lower phagocytosis rate of monocytes at 2:00 p.m. compared to 8:00 a.m. Moreover, the ATCo>10 group presented lower hemoglobin, mean corpuscular hemoglobin concentration, platelet and leukocyte levels, and increased cortisol concentrations at 8:00 a.m. compared to the other groups. Additionally, this group had lower phagocytosis rate of monocytes, and hemoglobin, platelet, leukocyte, basophils and nitric oxide levels at 2:00 p.m. compared to the other groups. CONCLUSION: Stress seems to greatly affect immune responses of air traffic controllers with more than ten years of experience.
  • The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia Original Articles

    Alegretti, Ana Paula; Bittar, Christina Matzenbacher; Bittencourt, Rosane; Piccoli, Amanda Kirchner; Schneider, Laiana; Silla, Lúcia Mariano; Bó, Suzane Dal; Xavier, Ricardo Machado

    Resumo em Inglês:

    BACKGROUND: The expression of CD56 is considered a bad prognostic factor for overall survival, lower rates or short complete remission and extramedullary invasion but the results are controversial. The importance of validating new prognostic parameters in acute leukemias was the reason to investigate the CD56 expression in blast cells of patients with acute myeloid leukemia. METHODS: A cohort of 48 patients treated at Hospital de Clinicas de Porto Alegre and diagnosed with acute myeloid leukemia as classified by the French-American-British group (FAB) criteria using cell morphology, cytochemistry and flow cytometry were evaluated. RESULTS: Eight cases (16.7%) were CD56 positive without correlation to age or gender. The highest incidence of CD56 positivity was in FAB subtypes M4 and M5. The death rate during induction was not significantly different between patients with and without CD56 expression (62.5% vs. 27.5%; p-value = 0.097). However, patients that expressed CD56 had significantly lower overall survival than those who did not (mean 4.0 months vs. 14.5 months; p-value = 0.03). CONCLUSIONS: The data suggest that expression of CD56 in acute myeloid leukemia may be indicative of poor prognosis because it is associated with a shorter overall survival. The death rate during induction was not significantly different despite an apparent difference in proportions between groups.
  • Analysis of oxidative status and biochemical parameters in adult patients with sickle cell anemia treated with hydroxyurea, Ceará, Brazil Original Articles

    Neto, Paulo Florentino Teixeira; Gonçalves, Romélia Pinheiro; Elias, Darcielle Bruna Dias; Araújo, Cleiton Pinheiro de; Magalhães, Hemerson Iury Ferreira

    Resumo em Inglês:

    BACKGROUND: Sickle cell anemia is a hemoglobinopathy caused by a mutation that results in the production of an abnormal hemoglobin molecule, hemoglobin S (Hb S). This is responsible for profound physiological changes, such as the sickling of red blood cells. Several studies have shown that hydroxyurea protects against vaso-occlusive crises. OBJECTIVE: The aim of this study was to evaluate the oxidative stress associated with biochemical parameters in patients with sickle cell anemia treated with hydroxyurea. METHODS: The study was conducted with 20 male and 25 female patients at the Hospital Universitário Walter Cantídio. The patients were divided into two groups: a study group (n = 12), patients with sickle cell anemia who were receiving hydroxyurea and a control group (n = 33) of sickle cell anemia patients not submitted to hydroxyurea treatment. The biochemical parameters analyzed were ferritin, transferrin, and serum iron. Glutathione was measured in its reduced form to analyze the oxidative state. RESULTS: The results showed insignificant increases in the levels of serum iron, transferrin and ferritin in patients treated with hydroxyurea when compared with those who did not take the medication. However, the glutathione levels were significantly higher in patients taking hydroxyurea than in controls. CONCLUSION: These results indicate that hydroxyurea possibly acts as an antioxidant by increasing glutathione levels.
  • Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase: the importance of a major molecular response Original Articles

    Machado, Melissa Pereira; Tomaz, Juarez Pires; Lorand-Metze, Irene; Souza, Cármino Antonio de; Vigorito, Afonso Celso; Delamain, Marcia Torresan; Bendit, Israel; Pereira, Noemi Farah; Pagnano, Katia Borgia Barbosa

    Resumo em Inglês:

    BACKGROUND: Real time PCR has become the most common technique to monitor BCR-ABL transcript levels of patients treated with kinase inhibitors. The aim of this study was to evaluate BCR-ABL levels of chronic myeloid leukemia patients treated with imatinib in the chronic phase and correlate the response to therapy and event-free survival. METHODS: BCR-ABL levels were measured in peripheral blood cell samples using Real time PCR at diagnosis and then every 3 months after starting therapy with imatinib. Major molecular response was defined as a three-log reduction from the standardized baseline value. Major molecular response values were adjusted to international scale using a conversion factor of 1.19. The results are reported as a BCR-ABL/ABL ratio (%). RESULTS: Hematological, major cytogenetic and complete cytogenetic responses were achieved by 57 (95%), 45 (75%) and 38 (63%) patients, respectively. Twenty-four out of sixty patients achieved a major molecular response (40%) in a median time of 8.5 months. Overall survival and event free survival were higher for patients with (100%) versus patients without (77%) a complete cytogenetic response (p-value = 0.01) at 48 months. Patients with complete cytogenetic response and major molecular response had a higher event free survival compared to patients with complete cytogenetic response but without major molecular response (p-value = 0.007). CONCLUSION: In conclusion, the prognostic impact of achieving complete cytogenetic response and a major molecular response and also the importance of molecular monitoring in the follow-up of chronic myeloid leukemia patients were demonstrated.
  • The role of natural killer cells in chronic myeloid leukemia Review Articles

    Danier, Anna Carolyna Araújo; Melo, Ricardo Pereira de; Napimoga, Marcelo Henrique; Laguna-Abreu, Maria Theresa Cerávolo

    Resumo em Inglês:

    Chronic myeloid leukemia is a neoplasia resulting from a translocation between chromosomes 9 and 22 producing the BCR-ABL hybrid known as the Philadelphia chromosome (Ph). In chronic myeloid leukemia a proliferation of malignant myeloid cells occurs in the bone marrow due to excessive tyrosine kinase activity. In order to maintain homeostasis, natural killer cells, by means of receptors, identify the major histocompatibility complex on the surface of tumor cells and subsequently induce apoptosis. The NKG2D receptor in the natural killer cells recognizes the transmembrane proteins related to major histocompatibility complex class I chain-related genes A and B (MICA and MICB), and it is by the interaction between NKG2D and MICA that natural killer cells exert cytotoxic activity against chronic myeloid leukemia tumor cells. However, in the case of chronic exposure of the NKG2D receptor, the MICA ligand releases soluble proteins called sMICA from the tumor cell surface, which negatively modulate NKG2D and enable the tumor cells to avoid lysis mediated by the natural killer cells. Blocking the formation of sMICA may be an important antitumor strategy. Treatment using tyrosine kinase inhibitors induces modulation of NKG2DL expression, which could favor the activity of the natural killer cells. However this mechanism has not been fully described in chronic myeloid leukemia. In the present study, we analyze the role of natural killer cells to reduce proliferation and in the cellular death of tumor cells in chronic myeloid leukemia.
  • Clinical applications of immunoglobulin: update Review Articles

    Novaretti, Marcia Cristina Zago; Dinardo, Carla Luana

    Resumo em Inglês:

    Human immunoglobulin is the most used blood product in the clinical practice. Immunoglobulin applications have increased quickly since the elucidation of its immunomodulatory and antiinflammatory properties which turned this blood product into a precious tool in the treatment of numerous diseases that present with humoral immune deficiency or that cause immune system dysfunction. Currently, the approved indications for Ig are: primary immunodeficiencies, secondary immunodeficiencies (multiple myeloma or chronic lymphoid leukemia), Kawasaki syndrome, immune thrombocytopenic purpura, Guillain Barré syndrome, graft-versus-host disease following bone marrow transplantation and repeat infections in HIV children. On the other hand, there are numerous "off-label" indications of immunoglobulin, which represent 20-60% of all clinical applications of this drug. It is important to study all these indications and, above all, the scientific evidence for its use, in order to provide patients with a new therapeutic option without burdening the health system. This review results from a wide selection of papers identified in the Pubmed and Lilacs scientific electronic databases. A group of descriptors were used from human immunoglobulin to the names of each disease that immunoglobulin is clinically applied. Our main objective is to list the numerous indications of immunoglobulin, both authorized and "off-label" and to analyze these indications in the light of the most recent scientific evidence.
  • What influences Hb fetal production in adulthood? Review Articles

    Carrocini, Gisele Cristine de Souza; Zamaro, Paula Juliana Antoniazzo; Bonini-Domingos, Claudia Regina

    Resumo em Inglês:

    Human hemoglobin genes are located in α and β globin gene clusters in chromosomes 16 and 11, respectively. Different types of hemoglobin are synthesized according to the stage of development with fetal hemoglobin (α2γ2) (Hb F) being the main hemoglobin in the fetal period. After birth, there is a reduction (to about 1%) in Hb F levels and adult hemoglobin, Hb A (2α2β2), increases to more than 96% of total hemoglobin. However, some genetic conditions whether linked to the β-globin gene cluster or not are associated with high Hb F levels in adults. Among those linked to β-globin are hereditary persistence of fetal hemoglobin, delta-beta thalassemia (δβ-Thalassemia) and the XmnI polymorphism (-158 C > T). Other polymorphisms not related to β-globin gene cluster are known to influence the γ-globin gene expression in adulthood. The most relevant polymorphisms that increase concentrations of Hb F are the HMIP locus on chromosome 6, the BCL11A locus on chromosome 2, the Xp22.2 region of the X chromosome and the 8q region on chromosome 8. Findings from our research group studying genetic factors involved in γ-globin gene regulation in adults without anemia in the northwestern region of São Paulo State showed that high Hb F levels are influenced by the presence of hereditary persistence of fetal hemoglobin mutations and the XmnI polymorphism, suggesting that both genetic alterations characterize the molecular basis of the evaluated population.
  • Advances in haploidentical stem cell transplantation Special Article

    Bayraktar, Ulas Darda; Lima, Marcos de; Ciurea, Stefan Octavian

    Resumo em Inglês:

    Hematopoietic stem cell transplantation from haploidentical donors is an attractive method of transplantation due to the immediate donor availability, ease of stem cell procurement and the possibility to collect additional donor cells for cellular therapy, if needed. Historically, maintaining T-cells in the graft has been associated with very high rates of graft-versus-host disease, while T-cell depleted haploidentical transplantation has been limited by a higher incidence of graft rejection and delayed immune reconstitution post-transplant. Recent approaches attempt to maintain the T-cells in the graft while effectively preventing the development of graft-versus-host disease post-transplant. Selective depletion of alloreactive T-cells post-transplant using high-dose post-transplant cyclophosphamide is under investigation as a promising alternative in haploidentical transplantation. While engraftment has improved and graft-versus-host disease is controlled with this approach, future directions should focus on optimizing conditioning regimens and the prevention of disease relapse post-transplant.
  • Monitoring strategy as a tool for blood transfusion safety Letter To Editor

    Daltoé, Tiago; Machado, Fabiani Palagi
  • Iron deficiency anemia and its treatment Letter To Editor

    Souza, Ariani Impieri de; Costa, Manuela Freire Hazin
  • Interaction between Hb SS and alpha thalassemia (3.7 kb deletion): a familial study Letter To Editor

    Shimauti, Eliana Litsuko Tomimatsu; Zamaro, Paula Juliana Antoniato; Bonini-Domingos, Claudia Regina
  • Iron deficiency anemia and its treatment: reply Letter To Editor

    Cançado, Rodolfo Delfini
  • Iron health: where are we and where are we going? Letter To Editor

    Gotardo, Glória Ines Beal
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular R. Dr. Diogo de Faria, 775 cj 114, 04037-002 São Paulo/SP/Brasil, Tel. (55 11) 2369-7767/2338-6764 - São Paulo - SP - Brazil
E-mail: secretaria@rbhh.org